SCHEDULE 13G/A 0000930413-25-000588 0001481867 XXXXXXXX LIVE 4 Common Stock, no par value 12/31/2025 0001892500 Clearmind Medicine Inc. 185053501 101-1220 West 6th Avenue Vancouver A1 V6H1A5 Rule 13d-1(c) Iroquois Capital Management, LLC DE 0.00 131886.00 0.00 131886.00 131886.00 N 8.1 OO Includes 131,886 shares of Common Stock issuable upon exercise of Warrants (See Item 4). As more fully described in Item 4, certain Warrants are subject to a 9.99% blocker (other than certain Warrants which are subject to a 4.99% blocker), and the percentage set forth in row (11) gives effect to such blockers. The shares reported in rows (6), (8) and (9) show the number of shares of Common Stock issuable upon exercise of such reported securities, giving effect to the 9.99% blocker. Richard Abbe X1 124876.00 131886.00 124876.00 131886.00 166464.00 N 9.99 HC IN Includes 166,464 shares of Common Stock issuable upon exercise of Warrants (See Item 4). As more fully described in Item 4, certain Warrants are subject to a 9.99% blocker (other than certain Warrants which are subject to a 4.99% blocker), and the percentage set forth in row (11) gives effect to such blockers. The shares reported in rows (5), (6), (7), (8) and (9) show the number of shares of Common Stock issuable upon exercise of such reported securities, giving effect to the 9.99% blocker. Kimberly Page X1 0.00 131886.00 0.00 131886.00 131886.00 N 8.1 IN Includes 131,886 shares of Common Stock issuable upon exercise of Warrants (See Item 4. As more fully described in Item 4, certain Warrants are subject to a 9.99% blocker (other than certain Warrants which are subject to a 4.99% blocker), and the percentage set forth in row (11) gives effect to such blockers. The shares reported in rows (6), (8) and (9) show the number of shares of Common Stock issuable upon exercise of such reported securities, giving effect to the 9.99% blocker. Clearmind Medicine Inc. 101-1220 West 6th Avenue, Vancouver, British Columbia V6H1A5 This statement is being filed by (i) Iroquois Capital Management LLC, a Delaware limited liability company ("Iroquois"), (ii) Richard Abbe, and (iii) Kimberly Page ("Mr. Abbe" and "Ms. Page," together with Iroquois, the "Reporting Persons"). Mr. Abbe shares authority and responsibility for the investments made on behalf of Iroquois Master Fund Ltd. ("Iroquois Master Fund") with Ms. Kimberly Page, each of whom is a director of the Iroquois Master Fund. As such, Mr. Abbe and Ms. Page may each be deemed to be the beneficial owner of all shares of Common Stock held by Iroquois Master Fund. Iroquois Capital is the investment advisor for Iroquois Master Fund and Mr. Abbe is the President of Iroquois Capital. Mr. Abbe has the sole authority and responsibility for the investments made on behalf of Iroquois Capital Investment Group LLC ("ICIG"). As such, Mr. Abbe may be deemed to be the beneficial owner of all shares of Common Stock held by Iroquois Master Fund and ICIG. The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of shares of Common Stock owned by another Reporting Person. The principal business address for each of the Reporting Persons is 2 Overhill Road, Scarsdale, NY 10583. Iroquois Capital Management LLC is a Delaware limited liability company. Richard Abbe is an individual who is a citizen of the United States of America. Kimberly Page is an individual who is a citizen of the United States of America. See Item 9 on the cover pages hereto. As of the date of the event which requires filing of this statement, Iroquois Master Fund held 0 shares of Common Stock and Reported Warrants to purchase 131,886 shares of Common Stock, and ICIG held 0 shares of Common Stock and Reported Warrants to purchase 124,876 shares of Common Stock. Pursuant to the terms of the Reported Warrants, the Reporting Persons cannot exercise the Reported Warrants to the extent the Reporting Persons would beneficially own, after any such exercise, more than 9.99% of the outstanding shares of Common Stock (other than certain Reported Warrants which are subject to a 4.99% blocker) (collectively, the "Blockers"). See Item 11 on the cover pages hereto. The percentage set forth in Row 11 of the cover page for each Reporting Person is based on 1,499,838 common shares outstanding as of January 19, 2026 as represented in the Company's Annual Report on Form 20-F filed with the Securities and Exchange Commission on January 20, 2026, and assumes the exercise of the Company's reported warrants (the "Reported Warrants"), each subject to the Blockers (as defined below). The percentage set forth in Item 11 of the cover page for each Reporting Person gives effect to the Blockers, if applicable. See Item 5 on the cover pages hereto. See Item 6 on the cover pages hereto. See Item 7 on the cover pages hereto. See Item 8 on the cover pages hereto. Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Iroquois Capital Management, LLC /s/ Richard Abbe 02/13/2026 Richard Abbe /s/ Richard Abbe 02/13/2026 Kimberly Page /s/ Kimberly Page 02/13/2026